These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 29941432)

  • 21. Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship.
    Harpe SE; Inocencio TJ; Pakyz AL; Oinonen MJ; Polk RE
    Pharmacotherapy; 2012 Aug; 32(8):744-54. PubMed ID: 23307522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of cross-infection associated to a Brazilian PCR-ribotype of Clostridium difficile in a university hospital in Rio de Janeiro, Brazil.
    Balassiano IT; dos Santos-Filho J; Vital-Brazil JM; Nouér SA; Souza CR; Brazier JS; Ferreira Ede O; Domingues RM
    Antonie Van Leeuwenhoek; 2011 Feb; 99(2):249-55. PubMed ID: 20623188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.
    Loo VG; Poirier L; Miller MA; Oughton M; Libman MD; Michaud S; Bourgault AM; Nguyen T; Frenette C; Kelly M; Vibien A; Brassard P; Fenn S; Dewar K; Hudson TJ; Horn R; René P; Monczak Y; Dascal A
    N Engl J Med; 2005 Dec; 353(23):2442-9. PubMed ID: 16322602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.
    Warny M; Pepin J; Fang A; Killgore G; Thompson A; Brazier J; Frost E; McDonald LC
    Lancet; 2005 Sep 24-30; 366(9491):1079-84. PubMed ID: 16182895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First report of Clostridium difficile NAP1/027 in a Mexican hospital.
    Camacho-Ortiz A; López-Barrera D; Hernández-García R; Galván-De Los Santos AM; Flores-Treviño SM; Llaca-Díaz JM; Maldonado-Garza HJ; Bosques-Padilla FJ; Garza-González E
    PLoS One; 2015; 10(4):e0122627. PubMed ID: 25915544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rifaximin in the treatment of recurrent Clostridium difficile infection.
    Mattila E; Arkkila P; Mattila PS; Tarkka E; Tissari P; Anttila VJ
    Aliment Pharmacol Ther; 2013 Jan; 37(1):122-8. PubMed ID: 23095030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiologic Trends in Clostridioides difficile Infections in a Regional Community Hospital Network.
    Turner NA; Grambow SC; Woods CW; Fowler VG; Moehring RW; Anderson DJ; Lewis SS
    JAMA Netw Open; 2019 Oct; 2(10):e1914149. PubMed ID: 31664443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular epidemiologic study of Clostridium difficile infections in university hospitals: Results of a nationwide study in Japan.
    Tokimatsu I; Shigemura K; Osawa K; Kinugawa S; Kitagawa K; Nakanishi N; Yoshida H; Arakawa S; Fujisawa M;
    J Infect Chemother; 2018 Aug; 24(8):641-647. PubMed ID: 29685855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy.
    Bouza E; Alcalá L; Marín M; Valerio M; Reigadas E; Muñoz P; González-Del Vecchio M; de Egea V
    Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1777-1786. PubMed ID: 28501926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter-based study on epidemiology, antibiotic susceptibility and risk factors of toxigenic Clostridium difficile in hospitalized patients in southwestern Iran.
    Sedigh Ebrahim-Saraie H; Heidari H; Amanati A; Bazargani A; Alireza Taghavi S; Nikokar I; Kalantar K; Motamedifar M
    Infez Med; 2018 Dec; 26(4):308-315. PubMed ID: 30555133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Burden of Clostridium difficile infection in the United States.
    Lessa FC; Mu Y; Bamberg WM; Beldavs ZG; Dumyati GK; Dunn JR; Farley MM; Holzbauer SM; Meek JI; Phipps EC; Wilson LE; Winston LG; Cohen JA; Limbago BM; Fridkin SK; Gerding DN; McDonald LC
    N Engl J Med; 2015 Feb; 372(9):825-34. PubMed ID: 25714160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea.
    Samore MH; Venkataraman L; DeGirolami PC; Arbeit RD; Karchmer AW
    Am J Med; 1996 Jan; 100(1):32-40. PubMed ID: 8579084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An epidemic, toxin gene-variant strain of Clostridium difficile.
    McDonald LC; Killgore GE; Thompson A; Owens RC; Kazakova SV; Sambol SP; Johnson S; Gerding DN
    N Engl J Med; 2005 Dec; 353(23):2433-41. PubMed ID: 16322603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole.
    Adler A; Miller-Roll T; Bradenstein R; Block C; Mendelson B; Parizade M; Paitan Y; Schwartz D; Peled N; Carmeli Y; Schwaber MJ
    Diagn Microbiol Infect Dis; 2015 Sep; 83(1):21-4. PubMed ID: 26116225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates.
    Walkty A; Boyd DA; Gravel D; Hutchinson J; McGeer A; Moore D; Simor A; Suh K; Taylor G; Miller M; Mulvey MR;
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):419-24. PubMed ID: 20226332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents.
    Riggs MM; Sethi AK; Zabarsky TF; Eckstein EC; Jump RL; Donskey CJ
    Clin Infect Dis; 2007 Oct; 45(8):992-8. PubMed ID: 17879913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clostridium difficile outbreak caused by NAP1/BI/027 strain and non-027 strains in a Mexican hospital.
    Morfin-Otero R; Garza-Gonzalez E; Aguirre-Diaz SA; Escobedo-Sanchez R; Esparza-Ahumada S; Perez-Gomez HR; Petersen-Morfin S; Gonzalez-Diaz E; Martinez-Melendez A; Rodriguez-Noriega E;
    Braz J Infect Dis; 2016; 20(1):8-13. PubMed ID: 26620948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies.
    Parmar SR; Bhatt V; Yang J; Zhang Q; Schuster M
    J Oncol Pharm Pract; 2014 Jun; 20(3):172-82. PubMed ID: 23804627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Epidemiology of Clostridium difficile-associated disease (CDAD) in Salamanca].
    Siller-Ruiz M; Calvo-García N; Hernández-Egido S; María-Blázquez A; de Frutos-Serna M; García-Sánchez JE
    Rev Esp Quimioter; 2014 Jun; 27(2):122-6. PubMed ID: 24940894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Clostridium difficile infection caused by the NAP1/RT027 strain on severity and recurrence during an outbreak and transition to endemicity in a Mexican tertiary care center.
    Tamez-Torres KM; Torres-González P; Leal-Vega F; García-Alderete A; López García NI; Mendoza-Aguilar R; Galindo-Fraga A; Bobadilla-Del Valle M; Ponce de León A; Sifuentes-Osornio J
    Int J Infect Dis; 2017 Dec; 65():44-49. PubMed ID: 28986313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.